

CURRICULUM VITAE



PERSONAL INFORMATION

Name	Giuseppina Calareso
Fax	02 23902524
E-mail	Giuseppina.calareso@istitutotumori.mi.it
Nationality	Italian
Tax code	CLRGPP80L61F158C
Date of birth	21/07/1980

WORK EXPERIENCE

- | | |
|--------------------------------|--|
| • Dates (from – to) | 05/2013- TO PRESENT |
| • Name and address of employer | Dr. Alfonso Marchianò – Fondazione IRCCS “Istituto Nazionale Tumori”, Milano , Italy |
| • Type of business or sector | Public Health |
| • Occupation or position held | Radiologist |
| • Dates (from – to) | 01/2010-04/2013 |
| • Name and address of employer | Prof. M Bellomi, - IRCCS “Istituto Europeo di Oncologia”, Milano, Italy |
| • Type of business or sector | Freelance |
| • Occupation or position held | Radiologist |

EDUCATION AND TRAINING

- | | |
|--|---|
| • Dates (from – to) | 29/10/2009 |
| • Name and type of organisation providing education and training | University, Pavia , Italy |
| • Principal subjects/occupational skills covered | Radiologist |
| • Title of qualification awarded | Postgraduate certificate in Radiology and Imaging Diagnosis (70/70 cum laude) |
| • Dates (from – to) | 17/02/2005 |
| • Name and type of organisation providing education and training | University, Pavia , Italy |
| • Title of qualification awarded | Medical Degree |

MOTHER TONGUE	ITALIAN
----------------------	----------------

OTHER LANGUAGES

	English
• Reading skills	Good
• Writing skills	Good
• Verbal skills	Good

SCIENTIFIC WORKS

1. *The role of volumetry in sinonasal cancer response assessment to induction chemotherapy, results from two phase II non-randomized controlled prospective multicentric trials: SINTART-1 and SINTART-2*
Rondi P, Mattavelli D, Rampinelli V, Schreiber A, Orlandi E, Vischioni B, Iacovelli NA, Calareso G, Bergamini C, Alfieri S, Castelnuovo P, Battaglia P, Turri-Zanoni M, Nicolai P, Ferrari M, Licitra L, Bossi P, Farina D, Ravanelli M, Resteghini C.
Oral Oncol. 2025 Jul;166:107388. doi: 10.1016/j.oraloncology.2025.107388. Epub 2025 May 25. PMID:40418879.
2. *Neoadjuvant Chemotherapy VI-RADS Scores for Assessing Muscle-invasive Bladder Cancer Response to Neoadjuvant Immunotherapy with Multiparametric*
Brembilla G, Basile G, Cosenza M, Giganti F, Del Prete A, Russo T, Pennella R, Lavalle S, Raggi D, Mercinelli C, Tateo V, Cigliola A, Patanè D, Crupi E, Giannatempo P, Messina A, Calareso G, Martini A, Bandini M, Moschini M, Cardone G, Briganti A, Montorsi F, Necchi A, De Cobelli F
MRI. Radiology. 2024 Dec;313(3):e233020. doi:10.1148/radiol.233020. PMID: 39718497.
3. *Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal Cancer Index – A prospective multicentric study using imaging (ISAAC study).*
Pinto P, Moro F, Alcázar JL, Alessi S, Avesani G, Benesova K, Burgetova A, Calareso G, Chiappa V, Cibula D, Fagotti A, Franchi D, Frühauf F, Jarkovsky J, Kocian R, Lambert L, Masek M, Panico C, Pricolo P, Scambia G, Slama J, Testa AC, Urbinati AMV, Garcia JV, Vigorito R, Fischerová D.
Gynecol Oncol. 2024 Dec;191:132-142. doi: 10.1016/j.ygyno.2024.10.003. Epub 2024 Oct 10. PMID: 39393218.
4. *Cylindrical TGR as early radiological predictor of RLT progression in GEPNETs: a proof of concept.*
Scalorbi F, Garanzini EM, Calareso G, Marzi C, Di Rocco G, Argiroffi G, Baccini M, Pusceddu S, Marchianò A, Maccauro M.
Sci Rep. 2024 Jul 9;14(1):15782. doi: 10.1038/s41598-024-66668-9. PMID: 38982134;
PMCID: PMC11233714.
5. *Prediction of nonresectability using the updated Predictive Index value model assessed by imaging and surgery in tubo-ovarian cancer: a prospective multicenter ISAAC study.*
Moro F, Pinto P, Chiappa V, Testa AC, Alcázar JL, Franchi D, Benesova K, Jarkovsky J, Frühauf F, Borčinová M, Burgetova A, Masek M, Lambert L, Altmanova D, Avesani G, Panico C, Alessi S, Pricolo P, Vara García J, Palladino S, Vigorito R, Calareso G, Kocian R, Slama J, Vidal Urbinati AM, Raspagliesi F, Fagotti A, Scambia G, Cibula D, Fischerová D.
Am J Obstet Gynecol. 2024 Dec;231(6):632.e1-632.e14. doi: 10.1016/j.ajog.2024.06.047. Epub 2024 Jul 3. PMID: 38969200.
6. *Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVANT phase II trial*

(NCT03921671).

Proto C, Ganzinelli M, Manglaviti S, Imbimbo M, Galli G, Marabese M, Zollo F, Alvisi MF, Perrino M, Cordua N, Borea F, de Vincenzo F, Chella A, Cappelli S, Pardini E, Ballatore Z, Lucarelli A, Ambrosini E, Giuliano M, Pietroluongo E, Mulargiu C, Fabbri A, Prelaj A, Occhipinti M, Brambilla M, Mazzeo L, Beninato T,

Vigorito R, Ruggirello M, Greco FG, Calareso G, Miliziano D, Rulli E, De Simone

I, Torri V, de Braud FGM, Pasello G, De Placido P, Berardi R, Petrini I, Zucali P, Garassino MC, Lo Russo G.

Ann Oncol. 2024 Sep;35(9):817-826. doi: 10.1016/j.annonc.2024.06.002. Epub 2024 Jun 8. PMID: 38857846.

7. MRI radiomics in head and neck cancer from reproducibility to combined approaches.

Corti A, Cavalieri S, Calareso G, Mattavelli D, Ravanelli M, Poli T, Licitra L, Corino VDA, Mainardi L.

Sci Rep. 2024 Apr 24;14(1):9451. doi:

10.1038/s41598-024-60009-6. PMID: 38658630; PMCID: PMC11043398.

8. Patient satisfaction with ultrasound, whole-body CT and whole-body diffusion-weighted

MRI for pre-operative ovarian cancer staging: a multicenter prospective cross-sectional survey.

Pinto P, Valentin L, Borčinová M, Wiesnerová M, Filip F, Burgetova A, Masek M, Lambert L, Chiappa V, Franchi D, Testa AC, Moro F, Avesani G, Panico C, Alessi S, Pricolo P, Vigorito R, Calareso G, Kocian R, Slama J, Fagotti A, Urbinati AMV, Signorelli M, Bertolina F, Cibula D, Fischerova D

Int J Gynecol Cancer. 2024 Jun 3;34(6):871-878. doi:

10.1136/ijgc-2023-005264. PMID: 38531539.

9: Developing a robust two-step machine learning multiclassification pipeline to predict primary site in head and neck carcinoma from lymph nodes. Heliyon.

Liu J, Corti A, Calareso G, Spadarella G, Licitra L, Corino VDA, Mainardi L.

2024 Jan 12;10(2):e24377. doi: 10.1016/j.heliyon.2024.e24377. PMID:

38312621; PMCID:

PMC10835257.

10. APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research. Clin Lung Cancer.

Prelaj A, Ganzinelli M, Provenzano L, Mazzeo L, Viscardi G, Metro G, Galli G, Agustoni F, Corte CMD, Spagnoletti A, Giani C, Ferrara R, Proto C, Brambilla

M, Dumitrascu AD, Inno A, Signorelli D, Pizzutilo EG, Brighenti M, Biello F, Bennati C, Toschi L, Russano M, Cortellini A, Catania C, Bertolini F, Berardi R, Cantini L, Pecci F, Macerelli M, Emili R, Bareggi C, Verderame F, Lugini A, Pisconti S, Buzzacchino F, Aieta M, Tartarone A, Spinelli G, Vita E, Grisanti S, Trovò F, Auletta P, Lorenzini D, Agnelli L, Sangaletti S, Mazzoni F, Calareso G,

Ruggirello M, Greco GF, Vigorito R, Occhipinti M, Manglaviti S, Beninato T, Leporati R, Ambrosini P, Serino R, Silvestri C, Zito E, Pedrocchi ACL, Miskovic V, de Braud F, Pruner G, Lo Russo G, Genova C, Vingiani A.

2024 Mar;25(2):190-195. doi: 10.1016/j.clcc.2023.12.012. Epub 2023 Dec 22.

PMID:
38262770.

11. *Multidisciplinary management of pregnancy-associated and early post-partum head and neck cancer patients.*

Bergamini C, Cavalieri S, Resteghini C, Alfieri S, Nuzzolese I, Colombo E, Ottini A, Calareso G, Vingiani A, Iacovelli NA, Franceschini M, Guzzo M, Deganello A, Licitra L

Front Oncol. 2023 Nov 22;13:1298439. doi: 10.3389/fonc.2023.1298439.

PMID: 38074678; PMCID:PMC10703464.

12. *Using Radiomics and Machine Learning Applied to MRI to Predict Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer.*

Diagnostics (Basel).

Chiappa V, Bogani G, Interlenghi M, Vittori Antisari G, Salvatore C, Zanchi L, Ludovisi M, Leone Roberti Maggiore U, Calareso G, Haeusler E, Raspagliesi F, Castiglioni I.

2023 Oct 6;13(19):3139. doi: 10.3390/diagnostics13193139.PMID: 37835882;

PMCID: PMC10572442.

13. *Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.*

Necchi A, Basile G, Gibb EA, Raggi D, Calareso G, de Padua TC, Patanè D, Crupi E, Mercinelli C, Cigliola A, Tateo V, Giannatempo P, Moschini M, Briganti A, Montorsi F, Messina A, Ross JS, Pavlick D, De Cobelli F, Brembilla G.

Vesical BJU Int. 2024Feb;133(2):214-222. doi: 10.1111/bju.16191. Epub 2023 Oct 16. PMID: 37803523.

14. *Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience.*

Cavalieri S, Platini F, Barretta F, Nuzzolese I, Ottini A, Bergamini C, Resteghini C, Colombo E, Iacovelli NA, Franceschini M, Calareso G, Di Pede P, De

Feo G, Gandelli M, Toffolatti L, Guglielmo M, Ripamonti CI, Cosmai L, Licitra L, Alfieri S.

Oral Oncol. 2023 Nov;146:106579. doi: 10.1016/j.oraloncology.2023.106579.

Epub 2023 Sep 29. PMID:37778228.

15. *NUT carcinoma of the submandibular gland: A case report.*

Rota S, Quattrone P, Centonze G, Dagrada G, Ottini A, Colombo E, Nuzzolese I, Calareso G, Franceschini M, Iacovelli NA, Perrone F, Tamborini E, Cavalieri S.

Cancer Rep (Hoboken). 2023 Dec;6(12):e1900. doi: 10.1002/cnr2.1900. Epub 2023 Sep 8. PMID: 37680121; PMCID: PMC10728538.

16. *MRI-based radiomic prognostic signature for locally advanced oral cavity squamous cell carcinoma: development, testing and comparison with genomic prognostic signatures.*

Corti A, De Cecco L, Cavalieri S, Lenoci D, Pistore F, Calareso G, Mattavelli D, de Graaf P, Leemans CR, Brakenhoff RH, Ravanelli M, Poli T, Licitra L, Corino

V, Mainardi L.

Biomark Res. 2023 Jul 16;11(1):69. doi: 10.1186/s40364-023-00494-5. PMID: 37455307; PMCID:PMC10350277.

17. *The SINTART 1 study. A phase II non-randomised controlled trial of induction chemotherapy, surgery, photon-, proton- and carbon ion-based radiotherapy integration in patients with locally advanced resectable sinonasal tumours.*

Resteghini C, Castelnovo P, Nicolai P, Orlandi E, Bossi P, Vischioni B, Schreiber A, Gambazza S, Iacovelli NA, Battaglia P, Guzzo M, Turri-Zanoni M, Mattavelli D, Facchinetti N, Calareso G, Ravanelli M, Facco C, Tartaro T, Licitra L.

Eur J Cancer. 2023 Jul;187:185-194. doi: 10.1016/j.ejca.2023.03.033.

Epub 2023 Apr 5. PMID: 37164774.

18. *The SINTART 2 Study. A phase II non-randomised controlled trial of induction chemotherapy, photon-, proton- and carbon-ion-based radiotherapy integration in patients with locally advanced unresectable sinonasal tumours.*

Bossi P, Orlandi E, Resteghini C, Vischioni B, Nicolai P, Castelnovo P, Gambazza S, Locati LD, Turri-Zanoni M, Ferrari M, Facchinetti N, Iacovelli NA, Calareso G, Quattrone P, Cavallo A, Tuzi A, Licitra L.

Eur J Cancer. 2023 Jul;187:134-143. doi: 10.1016/j.ejca.2023.03.034. Epub 2023 Apr 7. PMID: 37163806.

19: *STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines.*

Proto C, Manglaviti S, Lo Russo G, Musca M, Galli G, Imbimbo M, Perrino M, Cordua N, Rulli E, Ballatore Z, Maso AD, Chella A, Sbrana A, Prelaj A, Ferrara R, Occhipinti M, Brambilla M, De Toma A, Mazzeo L, Beninato T, Signorelli D, Massa G, Greco FG, Calareso G, Miliziano D, Di Mauro RM, Mella G, Lucarelli A,

Paggio A, Galli F, Torri V, de Braud FGM, Pasello G, Petrini I, Berardi R, Ganzinelli M, Garassino MC, Zucali PA.

J Thorac Oncol. 2023 Aug;18(8):1070-1081. doi: 10.1016/j.jtho.2023.04.009.

Epub 2023 Apr 23. PMID: 37094664.

20. *Prognostic radiomic signature for head and neck cancer: Development and validation on a multi-centric MRI dataset.*

Bologna M, Corino V, Cavalieri S, Calareso G, Gazzani SE, Poli T, Ravanelli M, Mattavelli D, de Graaf P, Nauta I, Scheckenbach K, Licitra L, Mainardi L.

Radiother Oncol. 2023 Jun;183:109638. doi: 10.1016/j.radonc.2023.109638.

Epub 2023 Mar 31. PMID: 37004837.

21. *HER2 status in recurrent/metastatic androgen receptor overexpressing salivary*

gland carcinoma patients. Cavalieri S, Nuzzolese I, Ottini A, Bergamini C, Resteghini C, Colombo E,

Alfieri S, Quattrone P, Calareso G, Iacovelli NA, Franceschini M, Licitra L.

Front Oncol. 2023 Jan 17;12:1096068. doi:10.3389/fonc.2022.1096068. PMID: 36733354; PMCID: PMC9887140.

22. *The Interplay between Age and Viral Status in EBV-Related Nasopharyngeal and HPV-Related Oropharyngeal Carcinoma Patients.*

Cavalieri S, Bossi P, Infante G, Miceli R, Iacovelli NA, Ivaldi E, Locati LD, Bergamini C, Resteghini C, Nuzzolese I, Alfieri S, Colombo E, Ingargiola R, Franceschini M, Calareso G, Licitra L, Orlandi E. *Cancers* (Basel). 2022 Dec 14;14(24):6170. doi:10.3390/cancers14246170. PMID: 36551656; PMCID: PMC9777049.

23. *Repeatability and reproducibility of MRI-radiomic features: A phantom experiment on a 1.5 T scanner.*

Bologna M, Tenconi C, Corino VDA, Annunziata G, Orlandi E, Calareso G, Pignoli E, Valdagni R, Mainardi LT, Rancati T. *Med Phys.* 2023 Feb;50(2):750-762. doi: 10.1002/mp.16054. Epub 2022 Nov 9. PMID: 36310346.

24. *Relapsing pediatric non-rhabdomyosarcoma soft tissue sarcomas: The impact of routine imaging surveillance on early detection and post-relapse survival.* Morosi C, Bergamaschi L, Livellara V, Hassan V, Chiaravalli S, Calareso G,

Luksch R, Terenziani M, Spreafico F, Meazza C, Podda M, Biassoni V, Schiavello E, Puma N, Gattuso G, Sironi G, Nigro O, Vennarini S, Massimino M, Casanova M, Ferrari A. *Eur J Cancer.* 2022 Nov;175:274-281. doi: 10.1016/j.ejca.2022.08.028. Epub 2022 Sep 26. PMID: 36174299.

25. *Case Report: Exceptional Response to Pozitotinib in Patient with Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation.*

Prelaj A, Bottiglieri A, Bhat G, Washington R, Calareso G, Greco GF, Ferrara R, Brambilla M, De Toma A, Occhipinti M, Manglaviti S, Soro A, Ganzinelli M, Lo Russo G, Proto C. *Front Oncol.* 2022 Jun 8;12:902967. doi: 10.3389/fonc.2022.902967. PMID: 35756673; PMCID: PMC9215205.

26. *The impact of radiomics for human papillomavirus status prediction in oropharyngeal*

cancer: systematic review and radiomics quality score assessment.

Spadarella G, Uggla L, Calareso G, Villa R, D'Aniello S, Cuocolo R. *Neuroradiology.* 2022 Aug;64(8):1639-1647. doi: 10.1007/s00234-022-02959-0. Epub 2022 Apr 23. PMID: 35459957; PMCID: PMC9271107.

27: *Refining Tumor Treatment in Sinonasal Cancer Using Delta Radiomics of Multi-Parametric MRI after the First Cycle of Induction Chemotherapy.*

Corino VDA, Bologna M, Calareso G, Resteghini C, Sdao S, Orlandi E, Licitra L, Mainardi L, Bossi P. *J Imaging.* 2022 Feb 15;8(2):46. doi: 10.3390/jimaging8020046. PMID: 35200748; PMCID: PMC8877083.

28: Defachelles AS, Bogart E, Casanova M, Merks JHM, Bisogno G, Calareso G, Melcon SG, Gatz SA, Le Deley MC, McHugh K, Probst A, Rocourt N, van Rijn

RR,
Minard-Colin V, Chisholm JC. Reply to H. B et al. J Clin Oncol. 2022 Mar 20;40(9):1030-1032. doi: 10.1200/JCO.21.02612. Epub 2022 Feb 7. PMID: 35130027.

29. *Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-*

Expressing Salivary Gland Cancer: A Phase II Trial.

Locati LD, Cavalieri S, Bergamini C, Resteghini C, Colombo E, Calareso G, Mariani L, Quattrone P, Alfieri S, Bossi P, Platini F, Capone I, Licitra L. J Clin Oncol. 2021 Dec 20;39(36):4061-4068. doi: 10.1200/JCO.21.00468. Epub 2021 Oct 1. PMID: 34597119; PMCID: PMC8677956.

30. *MRI Characteristics of Pediatric Renal Tumors: A SIOP-RTSG Radiology Panel Delphi Study.*

Van der Beek JN, Watson TA, Nievelstein RAJ, Brisse HJ, Morosi C, Lederman HM, Coma A, Gavra MM, Vult von Steyern K, Lakatos K, Breysen L, Varga E, Ducou Le Pointe H, Lequin MH, Schäfer JF, Mentzel HJ, Hötter AM, Calareso G, Swinson S, Kyncl M, Granata C, Aertsen M, Di Paolo PL, de Krijger RR, Graf N, Olsen ØE, Schenk JP, van den Heuvel-Eibrink MM, Littooij AS. J Magn Reson Imaging. 2022 Feb;55(2):543-552. doi: 10.1002/jmri.27878. Epub 2021 Aug 6. PMID: 34363274; PMCID: PMC9291546.

31. *Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.*

Defachelles AS, Bogart E, Casanova M, Merks JHM, Bisogno G, Calareso G, Gallego Melcon S, Gatz SA, Le Deley MC, McHugh K, Probst A, Rocourt N, van Rijn RR, Wheatley K, Minard-Colin V, Chisholm JC. J Clin Oncol. 2021 Sep 20;39(27):2979-2990. doi: 10.1200/JCO.21.00124. Epub 2021 Aug 3. PMID: 34343032.

32. *A Prospectively Validated Prognostic Model for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Based on Radiomics of Computed Tomography Images.*

Keek SA, Wesseling FWR, Woodruff HC, van Timmeren JE, Nauta IH, Hoffmann TK, Cavalieri S, Calareso G, Primakov S, Leijenaar RTH, Licitra L, Ravanelli M, Scheckenbach K, Poli T, Lanfranco D, Vergeer MR, Leemans CR, Brakenhoff RH, Hoebers FJP, Lambin P. Cancers (Basel). 2021 Jun 29;13(13):3271. doi: 10.3390/cancers13133271. PMID: 34210048; PMCID: PMC8269129.

33. *A CT-Based Radiomic Signature Can Be Prognostic for 10-Months Overall Survival in*

Metastatic Tumors Treated with Nivolumab: An Exploratory Study. Corino VDA, Bologna M, Calareso G, Licitra L, Ghi M, Rinaldi G, Caponigro F, Morelli

F, Airoidi M, Allegrini G, Cassano A, Ferrari D, Mirabile A, Tosoni A, Galizia D, Merlano M, Sponghini A, Moretti G, Mainardi L, Bossi P.
Diagnostics (Basel). 2021 May 28;11(6):979. doi:
10.3390/diagnostics11060979. PMID:
34071518; PMCID: PMC8229740.

34. *Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients.*

Alfieri S, Romanò R, Bologna M, Calareso G, Corino V, Mirabile A, Ferri A, Bellanti L, Poli T, Marcantoni A, Grosso E, Tarsitano A, Battaglia S, Blengio F, De Martino I, Valerini S, Vecchio S, Richetti A, Deantonio L, Martucci F, Grammatica A, Ravanelli M, Ibrahim T, Caruso D, Locati LD, Orlandi E, Bossi P, Mainardi L, Licitra LF.
Acta Oncol. 2021 Sep;60(9):1192-1200. doi:
10.1080/0284186X.2021.1924401. Epub 2021 May 26. PMID: 34038324.

35. *Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial.*

Marandino L, Raggi D, Calareso G, Alessi A, Colecchia M, Martini A, Briganti A, Montorsi F, Madison R, Ross JS, Necchi A
Clin Genitourin Cancer. 2021 Oct;19(5):457-465. doi:
10.1016/j.clgc.2021.04.001.
Epub 2021 Apr 21. PMID: 34006499.

36. *MRI based radiomics in nasopharyngeal cancer: Systematic review and perspectives using radiomic quality score (RQS) assessment.*

Spadarella G, Calareso G, Garanzini E, Ugga L, Cuocolo A, Cuocolo R.
Eur J Radiol. 2021 Jul;140:109744. doi: 10.1016/j.ejrad.2021.109744. Epub 2021 Apr 30. PMID:
33962253.

37. *Multidisciplinary Management of Radiation-Induced Salivary Gland Carcinomas in the Modern Radiotherapy Era.*

Romanello DA, Imamguliyeva Z, Cavalieri S, Vischioni B, Gandola L, Iannalfi A, Iacovelli NA, Licitra L, Guzzo M, Piazza C, Lombardi D, Diletto B, Quattrone P, Calareso G, Locati LD, Orlandi E.
Cancers (Basel). 2020 Dec 14;12(12):3769. doi: 10.3390/cancers12123769. PMID: 33327563;
PMCID: PMC7765068.

38. *Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.*

Manca P, Corallo S, Randon G, Lonardi S, Cremolini C, Rimassa L, Bergamo F, Antoniotti C, Smirolto V, Zaniboni A, Murialdo R, Tampellini M, Tomasello G, Clavarezza M, Racca P, Antista M, Raimondi A, Prisciandaro M, Pagani F, Palermo F, Greco FG, Vaiani M, Di Bartolomeo M, de Braud F, Calareso G, Morano F, Pietrantonio F

Eur J Cancer. 2021 Feb;144:31-40. doi: 10.1016/j.ejca.2020.11.017. Epub 2020 Dec 13. PMID: 33321462.

39. *Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients.*

Iacovelli NA, Cicchetti A, Cavallo A, Alfieri S, Locati L, Ivaldi E, Ingargiola R, Romanello DA, Bossi P, Cavalieri S, Tenconi C, Meroni S, Calareso G, Guzzo M, Piazza C, Licitra L, Pignoli E, Carlo F, Orlandi E. Front Oncol. 2020 Sep 24;10:518110. doi: 10.3389/fonc.2020.518110. PMID: 33072562; PMCID: PMC7541899.

40. *Baseline MRI-Radiomics Can Predict Overall Survival in Non-Endemic EBV-Related Nasopharyngeal Carcinoma Patients. Cancers (Basel).*

Bologna M, Corino V, Calareso G, Tenconi C, Alfieri S, Iacovelli NA, Cavallo A, Cavalieri S, Locati L, Bossi P, Romanello DA, Ingargiola R, Rancati T, Pignoli E, Sdao S, Pecorilla M, Facchinetti N, Trama A, Licitra L, Mainardi L, Orlandi E. 2020 Oct 13;12(10):2958. doi: 10.3390/cancers12102958. PMID: 33066161; PMCID: PMC7601980.

41. *Methodology and technology for the development of a prognostic MRI-based radiomic model for the outcome of head and neck cancer patients.*

Bologna M, Corino V, Tenconi C, Facchinetti N, Calareso G, Iacovelli N, Cavallo A, Alfieri S, Cavalieri S, Fallai C, Valdagni R, Rancati T, Trama A, Licitra L, Orlandi E, Mainardi L. Annu Int Conf IEEE Eng Med Biol Soc. 2020 Jul;2020:1152-1155. doi: 10.1109/EMBC44109.2020.9176565. PMID: 33018191.

42. *Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment.*

Raggi D, Bandini M, Giannatempo P, Farè E, Marandino L, Colecchia M, Calareso G, Padovano B, Serafini G, Alessi A, Necchi A. Clin Genitourin Cancer. 2021 Jun;19(3):237-245.e2. doi: 10.1016/j.clgc.2020.08.007. Epub 2020 Aug 13. PMID:32980271.

43. *Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study.*

Giannatempo P, Raggi D, Marandino L, Bandini M, Farè E, Calareso G, Colecchia M, Gallina A, Ross JS, Alessi A, Briganti A, Montorsi F, Madison R, Necchi A. Ann Oncol. 2020 Dec;31(12):1764-1772. doi: 10.1016/j.annonc.2020.09.012. Epub 2020 Sep 23. PMID:32979512.

44. *Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands.*

Cavalieri S, Mariani L, Vander Poorten V, Van Breda L, Cau MC, Lo Vullo S, Alfieri S, Resteghini C, Bergamini C, Orlandi E, Calareso G, Clement P, Hauben E, Platini F, Bossi P, Licitra L, Locati LD. Eur J Cancer.2020 Sep;136:35-42. doi: 10.1016/j.ejca.2020.05.013. Epub

2020 Jul 3. PMID:
32629365.

45. *The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer.*

Bandini M, Calareso G, Raggi D, Marandino L, Colecchia M, Gallina A, Giannatempo P, Pederzoli F, Gandaglia G, Fossati N, Capitanio U, Colombo R, Salonia A, Briganti A, Montorsi F, De Cobelli F, Messina A, Necchi A. Eur Urol Oncol. 2021 Oct;4(5):829-833. doi: 10.1016/j.euo.2020.06.004. Epub 2020 Jun 27. PMID:32605888.

46. *Reduced-dose craniospinal irradiation is feasible for standard-risk adult medulloblastoma patients.*

Massimino M, Sunyach MP, Barretta F, Gandola L, Garegnani A, Pecori E, Spreafico F, Bonneville-Levard A, Meyronet D, Mottolese C, Boschetti L, Biassoni V, Schiavello E, Giussani C, Carrabba G, Diletto B, Pallotti F, Stefani R, Ferrari A, Terenziani M, Casanova M, Luksch R, Meazza C, Podda M, Chiaravalli S, Puma N, Bergamaschi L, Morosi C, Calareso G, Giangaspero F, Antonelli M, Buttarelli FR, Frappaz D. J Neurooncol. 2020 Jul;148(3):619-628. doi: 10.1007/s11060-020-03564-y. Epub 2020 Jun 21. PMID:32567042.

47. *Privacy-preserving distributed learning of radiomics to predict overall survival and HPV status in head and neck cancer.*

Bogowicz M, Jochems A, Deist TM, Tanadini-Lang S, Huang SH, Chan B, Waldron JN, Bratman S, O'Sullivan B, Riesterer O, Studer G, Unkelbach J, Barakat S, Brakenhoff RH, Nauta I, Gazzani SE, Calareso G, Scheckenbach K, Hoebers F, Wesseling FWR, Keek S, Sanduleanu S, Leijenaar RTH, Vergeer MR, Leemans CR, Terhaard CHJ, van den Brekel MWM, Hamming-Vrieze O, van der Heijden MA, Elhalawani HM, Fuller CD, Guckenberger M, Lambin P. Sci Rep. 2020 Mar 11;10(1):4542. doi: 10.1038/s41598-020-61297-4. PMID: 32161279; PMCID: PMC7066122.

48. *Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life.*

Locati LD, Galbiati D, Calareso G, Alfieri S, Singer S, Cavalieri S, Bergamini C, Bossi P, Orlandi E, Resteghini C, Platini F, Granata R, Quattrone P, Mancinelli M, Mariani L, Lo Vullo S, Licitra LF. Cancer. 2020 Jan 1;126(9):1888-1894. doi: 10.1002/cncr.32754. Epub 2020 Feb 7. PMID: 32031693.

49. *Relevance of apparent diffusion coefficient features for a radiomics-based prediction of response to induction chemotherapy in sinonasal cancer.*

Bologna M, Calareso G, Resteghini C, Sdao S, Montin E, Corino V, Mainardi L, Licitra L, Bossi P.

NMR Biomed. 2022 Apr;35(4):e4265. doi: 10.1002/nbm.4265. Epub 2020 Feb 3. PMID: 32009265.

50 . *Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study.*

Necchi A, Bandini M, Calareso G, Raggi D, Pederzoli F, Farè E, Colecchia M, Marandino L, Bianchi M, Gallina A, Colombo R, Fossati N, Gandaglia G, Capitanio U, Dehò F, Giannatempo P, Lucianò R, Salonia A, Madison R, Ali SM, Chung JH, Ross JS, Briganti A, Montorsi F, De Cobelli F, Messina A
Eur Urol. 2020 May;77(5):636-643. doi:10.1016/j.eururo.2019.12.016. Epub 2019 Dec 25. PMID: 31882281.

51. *Prognostic role of primary tumor, nodal neck, and retropharyngeal GTVs for unresectable sinonasal cancers treated with IMRT and chemotherapy.*

Ferella L, Cavallo A, Miceli R, Iacovelli NA, Giandini T, Pignoli E, Calareso G, Bossi P, Resteghini C, Gravina GL, Nicolai P, Castelnuovo P, Piazza C, Licitra L, Fallai C, Orlandi E.
Tumori. 2020 Feb;106(1):39-46. doi: 10.1177/0300891619868006. Epub 2019 Aug 27. PMID: 31451102.

52. *The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.*

Proto C, Signorelli D, Mallone S, Prelaj A, Lo Russo G, Imbimbo M, Galli G, Ferrara R, Ganzinelli M, Leuzzi G, Greco FG, Calareso G, Botta L, Gatta G, Garassino M, Trama A.
Clin Lung Cancer. 2019 Nov;20(6):e652-e660. doi: 10.1016/j.clcc.2019.06.019. Epub 2019 Jun 26. PMID: 31377142.

53. *Locally advanced epithelial sinonasal tumors: The impact of multimodal approach.*

Orlandi E, Cavalieri S, Granata R, Nicolai P, Castelnuovo P, Piazza C, Schreiber A, Turri-Zanoni M, Quattrone P, Miceli R, Infante G, Sessa F, Facco C, Calareso G, Iacovelli NA, Mattavelli D, Paderno A, Resteghini C, Locati LD, Licitra L, Bossi P.
Laryngoscope. 2020 Apr;130(4):857-865. doi:10.1002/lary.28202. Epub 2019 Aug 1. PMID: 31369156.

54. *Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract.*

Locati LD, Cavalieri S, Bergamini C, Resteghini C, Alfieri S, Calareso G, Bossi P, Perrone F, Tamborini E, Quattrone P, Granata R, Galbiati D, Platini F, Orlandi E, Mariani L, Licitra L.
Head Neck. 2019 Oct;41(10):3670-3676. doi: 10.1002/hed.25891. Epub 2019 Jul 29. PMID: 31355973.

55 . *Surveillance of Patients with Head and Neck Cancer with an Intensive*

Clinical and Radiologic Follow-up.

Imbimbo M, Alfieri S, Botta L, Bergamini C, Gloghini A, Calareso G, Orlandi E, Iacovelli NA, Guzzo M, Granata R, Resteghini C, Locati L, Volpi CC, Licitra L, Bossi P

Otolaryngol Head Neck Surg. 2019 Oct;161(4):635-642. doi: 10.1177/0194599819860808. Epub 2019 Jul 9. PMID:31286827.

56. *RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy.* Bogani G, Matteucci L, Tamberi S, Ditto A, Sabatucci I, Murgia F, Arcangeli V, Maltese G, Comerci G, Stefanetti M, Sonetto C, Calareso G, Marchiano A, Chiappa V, Lorusso D, Raspagliesi F.

Eur J Obstet Gynecol Reprod Biol. 2019 Jun;237:93-99. doi: 10.1016/j.ejogrb.2019.04.007. Epub 2019 Apr 8. PMID: 31029972.

57. *The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment.*

Siano M, Alfieri S, Granata R, Calareso G, Orlandi E, Bergamini C, Locati LD.

Tumori. 2019 Dec;105(6):NP28-NP31. doi: 10.1177/0300891619829571. Epub 2019 Feb 19. PMID: 30782103.

58. *Use of apparent diffusion coefficient images to predict response to induction chemotherapy in sinonasal cancer.*

Bologna M, Montin E, Corino VDA, Bossi P, Calareso G, Licitra L, Mainardi LT.

Annu Int Conf IEEE Eng Med Biol Soc. 2018 Jul;2018:782-785. doi: 10.1109/EMBC.2018.8512306. PMID: 30440511.

59. *Best practices for the management of thymic epithelial tumors: A position paper*

by the Italian collaborative group for ThYmic MalignanciEs (TYME).

Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello G, Perrino M, Schiavon M, Pruner G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R, Alessi A, Calareso G, Petrini I, Scorsetti M, Scotti V, Rosso L, Rea F, Pastorino U, Casali PG, Ramella S, Ricardi U, Abate-Daga L, Torri V, Trama A, Palmieri G, Marino M, Zucali PA; TYME network collaborators.

Cancer Treat Rev. 2018 Dec;71:76-87. doi: 10.1016/j.ctrv.2018.10.001. Epub 2018 Oct 5. PMID: 30366202.

60. *Big Data in Head and Neck Cancer.*

Resteghini C, Trama A, Borgonovi E, Hosni H, Corrao G, Orlandi E, Calareso G, De Cecco L, Piazza C, Mainardi L, Licitra L.

Curr Treat Options Oncol. 2018 Oct 25;19(12):62. doi:10.1007/s11864-018-0585-2. PMID: 30361937.

61. *An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis.*

Necchi A, Giannatempo P, Raggi D, Mariani L, Colecchia M, Farè E, Monopoli F, Calareso G, Ali SM, Ross JS, Chung JH, Salvioni R.

Eur Urol. 2019 Jan;75(1):201-203. doi:

10.1016/j.eururo.2018.09.010. Epub 2018 Sep 19. PMID: 30243800.

62. *Assessment of Stability and Discrimination Capacity of Radiomic Features on Apparent Diffusion Coefficient Images.*

Bologna M, Corino VDA, Montin E, Messina A, Calareso G, Greco FG, Sdao S, Mainardi LT.

J Digit Imaging. 2018 Dec;31(6):879-894. doi: 10.1007/s10278-018-0092-9.

PMID: 29725965; PMCID:

PMC6261192.

63.: *Different pixel pitch and maximum luminance of medical grade displays may result in different evaluations of digital radiography images.*

Laffranchi A, Cicero C, Lualdi M, Ciniselli CM, Calareso G, Canestrini S, Greco FG, Alberioli E, Cavatorta C, Guarise A, Pignoli E, Plebani M, Scaramuzza

D, Siciliano C, Verderio P, Marchianò A.

Radiol Med. 2018 Aug;123(8):586-592. doi:10.1007/s11547-018-0891-6. Epub 2018 Apr 18. PMID: 29671208.

64. *Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients.*

Romeo P, Colombo C, Granata R, Calareso G, Gualeni AV, Dugo M, De Cecco L,

Rizzetti MG, Zanframundo A, Aiello A, Carcangiu ML, Gloghini A, Ferrero S, Licitra L, Greco A, Fugazzola L, Locati LD, Borrello MG.

Endocr Relat Cancer. 2018 Mar;25(3):217-231. doi: 10.1530/ERC-17-0389.

Epub 2018

Jan 3. PMID: 29298817.

65. *First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.*

Necchi A, Lo Vullo S, Perrone F, Raggi D, Giannatempo P, Calareso G, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Togliardi E, Colecchia M, Busico A, Gloghini A, Testi A, Mariani L, Salvioni R

BJU Int. 2018 Mar;121(3):348-356. doi:10.1111/bju.14013. Epub 2017 Oct 4.

PMID: 28921872.

66. *Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.*

Necchi A, Lo Vullo S, Raggi D, Perrone F, Giannatempo P, Calareso G, Togliardi E, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Colecchia M, Busico A, Pennati M, Zaffaroni N, Mariani L, Salvioni R.

Urol Oncol. 2018 Jan;36(1):8.e1-8.e8. doi: 10.1016/j.urolonc.2017.08.020.

Epub 2017 Sep 12. PMID: 28911922.

67. *Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?*

Grassi P, Verzoni E, Ratta R, Porcu L, Prisciandaro M, Mennitto A, Calareso G, de Braud F, Procopio G.

Drugs R D. 2017 Sep;17(3):461-467. doi: 10.1007/s40268-017-0203-y. PMID:

28801802; PMCID: PMC5629143.

68. *Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma.*

Greco G, Cascella T, Facciorusso A, Nani R, Lanocita R, Morosi C, Vaiani M, Calareso G, Greco FG, Ragnanese A, Bongini MA, Marchianò AV, Mazzaferro V, Spreafico C.

World J Radiol. 2017 May 28;9(5):245-252. doi:10.4329/wjr.v9.i5.245. PMID: 28634515; PMCID: PMC5441456.

69. *Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial.*

Necchi A, Lo Vullo S, Giannatempo P, Raggi D, Calareso G, Togliardi E, Crippa F, Pennati M, Zaffaroni N, Perrone F, Busico A, Colecchia M, Nicolai N, Mariani L, Salvioni R.

Ann Oncol. 2017 Jun 1;28(6):1346-1351. doi: 10.1093/annonc/mdx124. PMID: 28383677.

70: *Treatment of advanced renal cell carcinoma: recent advances and current role of*

immunotherapy, surgery, and cryotherapy.

Mennitto A, Verzoni E, Calareso G, Spreafico C, Procopio G.

Tumori. 2017 Jan 21;103(1):15-21. doi:10.5301/tj.5000581. Epub 2016 Oct 26. PMID: 27791232.

71: *Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up.*

Vernieri C, Femia D, Pusceddu S, Capella C, Rosai J, Calareso G, Concas L, Prinzi N, Lo Russo G, de Braud F, Buzzoni R.

Case Rep Oncol. 2016 Aug 17;9(2):432-439. doi: 10.1159/000447771. PMID: 27721764;

PMCID: PMC5043191.

72: *Lung cancer screening with low-dose spiral computed tomography: evidence from a pooled analysis of two Italian randomized trials.*

Infante M, Sestini S, Galeone C, Marchianò A, Lutman FR, Angeli E, Calareso G, Pelosi G, Sozzi G, Silva M, Sverzellati N, Cavuto S, La Vecchia C, Santoro A,

Alloisio M, Pastorino U.

Eur J Cancer Prev. 2017 Jul;26(4):324-329. doi: 10.1097/CEJ.0000000000000264.

PMID: 27222939; PMCID: PMC6861837.

73 . *Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma.*

Massimino M, Miceli R, Giangaspero F, Boschetti L, Modena P, Antonelli M, Ferroli P, Bertin D, Pecori E, Valentini L, Biassoni V, Garrè ML, Schiavello E, Sardi I, Cama A, Viscardi E, Scarzello G, Scoccianti S, Mascarin M, Quaglietta L, Cinalli G, Diletto B, Genitori L, Peretta P, Mussano A, Buccoliero A, Calareso G, Barra S, Mastronuzzi A, Giussani C, Marras CE, Balter R, Bertolini P, Giombelli E, La Spina M, Buttarelli FR, Pollo B, Gandola L.

Neuro Oncol. 2016 Oct;18(10):1451-60. doi: 10.1093/neuonc/now108. Epub 2016 May

18. PMID: 27194148; PMCID: PMC5035526.

74. *Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy*

Failure. Necchi A, Anichini A, Raggi D, Giannatempo P, Magazzù D, Nicolai N, Colecchia M, Paolini B, Coradeschi E, Tassi E, Grazia G, Mortarini R, Calareso G, De Fato R, Togliardi E, Crippa F, Salvioni R, Valagussa P, Gianni AM. Clin Genitourin Cancer. 2016 Aug;14(4):261-264.e4. doi: 10.1016/j.clgc.2016.03.020. Epub 2016 Mar 24. PMID: 27105722.

75: *Screening per il tumore polmonare in soggetti ad alto rischio: diagnosi precoce con TC spirale associata a stratificazione del rischio con miRNA circolanti [Lung cancer screening in high-risk subjects: early detection with LDCT and risk stratification using miRNA-based blood test].*

Sestini S, Boeri M, Marchianò A, Silva M, Calareso G, Galeone C, Sozzi G, Pastorino U.

Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 1):42-50. Italian. doi: 10.19191/EP16.1S1.P042.029.

Erratum in: Epidemiol Prev. 2019 Jul-Aug;43(4):219. doi: 10.19191/EP19.4.P219.085. PMID: 26951732.

76. *Stopping Smoking Reduces Mortality in Low-Dose Computed Tomography Screening Participants.*

Pastorino U, Boffi R, Marchianò A, Sestini S, Munarini E, Calareso G, Boeri M, Pelosi G, Sozzi G, Silva M, Sverzellati N, Galeone C, La Vecchia C, Ghirardi

A, Corrao G.

J Thorac Oncol. 2016 May;11(5):693-699. doi:10.1016/j.jtho.2016.02.011. Epub 2016 Feb 24. PMID: 26921675.

77: *An open-label, single-arm, phase2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer.*

Necchi A, Lo Vullo S, Mariani L, Raggi D, Giannatempo P, Calareso G, Togliardi E, Crippa F, Di Genova N, Perrone F, Colecchia M, Paolini B, Pelosi G,

Nicolai N, Procopio G, Salvioni R, De Braud FG.

Invest New Drugs. 2016 Apr;34(2):236-42. doi:10.1007/s10637-016-0328-9. Epub 2016 Feb 12. PMID: 26873642.

78. *Low-dose computed tomography for lung cancer screening: comparison of performance between annual and biennial screen.*

Sverzellati N, Silva M, Calareso G, Galeone C, Marchianò A, Sestini S, Sozzi G, Pastorino U.

Eur Radiol. 2016 Nov;26(11):3821-3829. doi: 10.1007/s00330-016-4228-3. Epub 2016 Feb 11. PMID:26868497.

79: *Screening with Low-Dose Computed Tomography Does Not Improve Survival of Small Cell Lung Cancer.*

Silva M, Galeone C, Sverzellati N, Marchianò A, Calareso G, Sestini S, La Vecchia C, Sozzi G, Pelosi G, Pastorino U.

J Thorac Oncol. 2016 Feb;11(2):187-93. doi: 10.1016/j.jtho.2015.10.014. Epub 2015 Dec 23. PMID:26845115.

80: *A case of relapsing spinal atypical teratoid/rhabdoid tumor (AT/RT)*

responding to vinorelbine, cyclophosphamide, and celecoxib.

Gotti G, Biassoni V, Schiavello E, Spreafico F, Antonelli M, Calareso G, Pecori E, Gandola L, Massimino M.

Childs Nerv Syst. 2015 Sep;31(9):1621-3. doi:10.1007/s00381-015-2755-x. Epub 2015 May 26. PMID: 26008576.

81: *Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation.*

Raggi D, Mariani L, Giannatempo P, Lo Vullo S, Giardiello D, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Calareso G, Magni

M, Di Nicola M, Verzoni E, Grassi P, Procopio G, De Braud F, Pizzocaro G, Salvioni R, Necchi A.

Urol Oncol. 2015 Jul;33(7):332.e19-24. doi:10.1016/j.urolonc.2015.04.008. Epub 2015 May 16. PMID: 25985712.

82 . *Small and large bowel hernia migrated into the chest 6 years after sternal resection.* Billè A, Scanagatta P, Gisabella M, Calareso G, Pastorino U.

Ann Thorac Surg. 2015;99(5):1823-5. doi: 10.1016/j.athoracsur.2014.06.117. PMID: 25952222.

83. *Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer.*

Platania M, Valeri B, Marchianò A, Calareso G, Agustoni F, Haspinger E, Pusceddu S, Garassino MC, Gelsomino F, de Braud F.

Int J Colorectal Dis. 2015 Mar;30(3):429-30. doi: 10.1007/s00384-014-1993-9. Epub 2014 Aug 21. PMID: 25139369.

84. *Pre-operative MR evaluation of features that indicate the need of adjuvant therapies in early stage cervical cancer patients. A single-centre experience.*

Rizzo S, Calareso G, Maccagnoni S, Angileri SA, Landoni F, Raimondi S, Pasquali E, Lazzari R, Bellomi M.

Eur J Radiol. 2014 May;83(5):858-64. doi: 10.1016/j.ejrad.2014.01.029. Epub 2014 Feb 7. PMID: 24581810.

85. *Gynecologic tumors: how to communicate imaging results to the surgeon.*

Rizzo S, Calareso G, De Maria F, Zanagnolo V, Lazzari R, Cecconi A, Bellomi M.

Cancer Imaging. 2013 Dec 30;13(4):611-25. doi: 10.1102/1470-7330.2013.0054. PMID: 24434038; PMCID: PMC3894699.

I declare to have experience in good clinical practice and in study coordination.

I authorize the treatment of my personal data, according to Italian laws (196/03)

I remain at your disposal,

Milan, Giugno 2025